STAT March 27, 2024
Good morning, everyone. Damian here with the details on a potentially major drug approval, an idea to make CAR-T more equitable, and the slow launch of a gene therapy.
The need-to-know this morning
- Blackstone Life Sciences said it will invest up to $750 million to support Moderna’s mRNA-based flu vaccine programs.
- The European academic “TUDCA” study in ALS failed to its primary goal of slowing disease progression. The study was designed to investigate one of the two drug ingredients in Amylyx Pharma’s Relyvrio, which also recently failed its own clinical trial.
Merck’s potential blockbuster gets a clean label
The FDA approved Merck’s new treatment for a rare cardiovascular disease yesterday, clearing a drug that could bring in nearly...
Today's Sponsors
Today's Sponsor